Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

20141,676 citationsJournal Articlebronze Open Access

Authors

Richard R. Furman · Georgetown University

Jeff P. Sharman · Cornell University

Steven Coutré · Stanford University

Bruce D. Cheson · Cornell University

John M. Pagel · Fred Hutch Cancer Center

Peter Hillmen · St James's University Hospital

Jacqueline C. Barrientos ·

Abstract

The combination of idelalisib and rituximab, as compared with placebo and rituximab, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy. (Funded by Gilead; ClinicalTrials.gov number, NCT01539512.).

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Chronic Myeloid Leukemia Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 11, pp. 997-1007

DOI: 10.1056/nejmoa1315226

Field-Weighted Citation Impact: 132.16